Petros Pharmaceuticals (PTPI) Competitors $0.25 0.00 (0.00%) (As of 11/21/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends PTPI vs. MBIO, KPRX, TRIB, CDT, SNTI, ONCO, AYTU, JAGX, ADXN, and RDHLShould you be buying Petros Pharmaceuticals stock or one of its competitors? The main competitors of Petros Pharmaceuticals include Mustang Bio (MBIO), Kiora Pharmaceuticals (KPRX), Trinity Biotech (TRIB), Conduit Pharmaceuticals (CDT), Senti Biosciences (SNTI), Onconetix (ONCO), Aytu BioPharma (AYTU), Jaguar Health (JAGX), Addex Therapeutics (ADXN), and RedHill Biopharma (RDHL). These companies are all part of the "pharmaceutical products" industry. Petros Pharmaceuticals vs. Mustang Bio Kiora Pharmaceuticals Trinity Biotech Conduit Pharmaceuticals Senti Biosciences Onconetix Aytu BioPharma Jaguar Health Addex Therapeutics RedHill Biopharma Petros Pharmaceuticals (NASDAQ:PTPI) and Mustang Bio (NASDAQ:MBIO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations, community ranking and risk. Does the MarketBeat Community prefer PTPI or MBIO? Mustang Bio received 168 more outperform votes than Petros Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Petros Pharmaceuticals an outperform vote while only 64.26% of users gave Mustang Bio an outperform vote. CompanyUnderperformOutperformPetros PharmaceuticalsOutperform Votes1100.00% Underperform VotesNo VotesMustang BioOutperform Votes16964.26% Underperform Votes9435.74% Is PTPI or MBIO more profitable? Petros Pharmaceuticals' return on equity of -78.22% beat Mustang Bio's return on equity.Company Net Margins Return on Equity Return on Assets Petros PharmaceuticalsN/A -78.22% -23.50% Mustang Bio N/A -1,243.22%-172.89% Do institutionals and insiders hold more shares of PTPI or MBIO? 12.3% of Petros Pharmaceuticals shares are owned by institutional investors. Comparatively, 10.0% of Mustang Bio shares are owned by institutional investors. 12.3% of Petros Pharmaceuticals shares are owned by insiders. Comparatively, 0.8% of Mustang Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media refer more to PTPI or MBIO? In the previous week, Mustang Bio had 3 more articles in the media than Petros Pharmaceuticals. MarketBeat recorded 3 mentions for Mustang Bio and 0 mentions for Petros Pharmaceuticals. Petros Pharmaceuticals' average media sentiment score of 0.00 beat Mustang Bio's score of -0.21 indicating that Petros Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Petros Pharmaceuticals Neutral Mustang Bio Neutral Which has more risk and volatility, PTPI or MBIO? Petros Pharmaceuticals has a beta of 2.11, meaning that its share price is 111% more volatile than the S&P 500. Comparatively, Mustang Bio has a beta of 1.92, meaning that its share price is 92% more volatile than the S&P 500. Which has higher earnings and valuation, PTPI or MBIO? Petros Pharmaceuticals has higher revenue and earnings than Mustang Bio. Mustang Bio is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPetros Pharmaceuticals$5.82M0.43-$8.16M-$4.76-0.05Mustang BioN/AN/A-$51.60M-$1.56-0.13 Do analysts recommend PTPI or MBIO? Petros Pharmaceuticals presently has a consensus price target of $4.00, indicating a potential upside of 1,500.64%. Mustang Bio has a consensus price target of $2.00, indicating a potential upside of 862.00%. Given Petros Pharmaceuticals' higher probable upside, analysts clearly believe Petros Pharmaceuticals is more favorable than Mustang Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Petros Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Mustang Bio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryPetros Pharmaceuticals beats Mustang Bio on 11 of the 14 factors compared between the two stocks. Ad DTIWhen it comes to NVDA… “acceleration cycles” are the keyExpert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.Use this link to see Nvidia Unchained right away! Get Petros Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PTPI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTPI vs. The Competition Export to ExcelMetricPetros PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.50M$6.52B$5.11B$8.84BDividend YieldN/A8.11%5.05%4.07%P/E Ratio-0.057.36108.8915.88Price / Sales0.43366.511,233.2287.15Price / CashN/A52.5939.9336.27Price / Book0.8110.176.946.36Net Income-$8.16M$153.36M$119.18M$226.00M7 Day Performance-7.55%-1.61%-1.36%-0.02%1 Month Performance-40.13%-7.15%-3.27%1.95%1 Year Performance-81.07%31.68%32.40%27.80% Petros Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTPIPetros Pharmaceuticals2.9627 of 5 stars$0.25flat$4.00+1,500.6%-80.9%$2.50M$5.82M-0.0520Gap UpMBIOMustang Bio1.9602 of 5 stars$0.21flat$2.00+862.0%-87.6%$9.93MN/A-0.13100KPRXKiora Pharmaceuticals3.0135 of 5 stars$3.31-3.2%$10.00+202.1%-32.4%$9.93MN/A0.0010TRIBTrinity Biotech1.8451 of 5 stars$1.30flatN/A-33.5%$9.91M$56.83M-0.58480CDTConduit PharmaceuticalsN/A$0.10+10.8%N/A-92.8%$9.81MN/A0.003News CoverageGap UpHigh Trading VolumeSNTISenti Biosciences1.0759 of 5 stars$2.12flatN/A-42.1%$9.73M$2.56M-0.144News CoverageONCOOnconetix0.2105 of 5 stars$1.15+6.5%N/AN/A$9.53M$60,000.000.0012AYTUAytu BioPharma1.3282 of 5 stars$1.51+1.3%N/A-37.9%$9.28M$81M-1.21160JAGXJaguar Health0.6751 of 5 stars$0.97-1.0%N/A-96.5%$8.96M$9.76M0.0050ADXNAddex Therapeutics2.6652 of 5 stars$8.25+11.8%$30.00+263.6%+23.6%$8.75M$1.83M0.0030RDHLRedHill Biopharma0.975 of 5 stars$6.74+5.3%N/A-96.9%$8.63M$6.53M0.00210News Coverage Related Companies and Tools Related Companies Mustang Bio Competitors Kiora Pharmaceuticals Competitors Trinity Biotech Competitors Conduit Pharmaceuticals Competitors Senti Biosciences Competitors Onconetix Competitors Aytu BioPharma Competitors Jaguar Health Competitors Addex Therapeutics Competitors RedHill Biopharma Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PTPI) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Petros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Petros Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
